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The  reproductive  toxicity  of combined  ﬁxed-dose  ﬁrst-line  antituberculosis  (CFDAT)  regimen  was
assessed  in rats.  Thirty-two  (32)  Wistar  rats  weighing  168.1  ± 8.0  g  were  divided  into  four  groups  of
eight  rats  per  group.  Two  groups  of male  and  female  rats  were  administered  oral  distilled  water  (1.6  ml)
and  CFDAT  drugs  containing  rifampicin,  isoniazid,  pyrazinamide  and  ethambutol  (RIPE,  92.5  mg/m2  per
body  surface  area)  respectively  for forty-ﬁve  days.  Serum  follicle  stimulating  hormone,  luteinizing  and
testosterone  were  reduced  signiﬁcantly  (p  <  0.05)  in  the  treated  male  rats.  Similarly,  sperm  count  levels
were decreased  by  27.3%  when  compared  with  control.  RIPE  elevated  serum  oestrogen  (p  < 0.05),  pro-
gesterone  (p <  0.05)  as well  as  prolactin  (p > 0.05)  levels  in  the  treated  females.  In addition,  RIPE reduced
(p  < 0.05)  total  proteins  levels  and  increased  (p <  0.05, 53%)  catalase  levels  in  male  but not female  animals.ats Superoxide  dismutase,  glutathione-S-transferase,  glutathione  peroxidase,  reduced  glutathione  levels  as
well  as  lipid  peroxidation  were  unaltered  in all rats  respectively.  Histopathological  studies  revealed  con-
gested  peritesticular  vessels  and  no  changes  in the  ovary  when  compared  with  control.  Overall,  our  results
demonstrate  reproductive  toxicity  potentials  of RIPE  in  the  rat, thus,  suggesting  that these  reproductive
parameters  be  monitored  during  antituberculous  chemotherapy.
©  2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC. Introduction
There have been recent suggestions that anti-tuberculosis
gents would produce adverse effects on reproductive health sys-
em [1–4]. Tuberculosis (TB), a Mycobacterium tuberculosis (M.
uberculosis) remains an epidemic in many parts of the world.
ccording to the WHO, an estimated 8.7 million new cases of TB
nd 1.4 million deaths from TB emerge in 2011[5]. TB is the lead-
ng cause of death from a curable infectious disease and is second
nly to HIV/AIDS as a cause of death from any infectious disease
7]. The rapid spread of drug-resistant TB in Asia, Eastern Europe,
nd Africa has limited the achievement of TB treatments goals
mong others [6,7]. TB incidence has been falling globally for sev-
∗ Corresponding author at: Consultant Toxicologist, Toxicology Unit, Department
f  Pharmacology, Therapeutics & Toxicology, College of Medicine, University of
agos, Lagos−Nigeria.
E-mail address: awodeleo@gmail.com (O. Awodele).
ttp://dx.doi.org/10.1016/j.toxrep.2016.06.007
214-7500/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
eral years and fell at an average rate of about 1.5% per year between
2000 and 2014. For instance, the TB mortality rate has fallen by
an estimated 47% between 1990 and 2015 [8]. It poses signiﬁcant
challenges to developing economies as it primarily affects peo-
ple during their most productive years. The treatment protocol
for drug-sensitive TB, however, varies slightly in different parts of
the world, but they are based on a combination of three, or more
typically, four drugs, i.e. isoniazid, rifampin, pyrazinamide, and
ethambutol. This combination has been adjudged best for efﬁcacy
and tolerability amongst the available TB drugs and is, therefore,
the mainstay “ﬁrst line” therapy [8,9]. There are historical and clin-
ical proofs that these ﬁrst-line antituberculosis agents are the most
potent oral antituberculous medications [10–12]. In addition, in-
vitro and in-vivo clinical data support the use of such individual
agent [13,14]. This may  be because the combination has been found
to be a beneﬁcial and cost-effective treatment for TB [15], but, this
is not without some systemic toxicity from the results from human
data [1,3,5]. A study from Sharma [16] suggests that the high inci-
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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ence of antituberculous drugs inducing toxicities may  indicate
ifﬁculties with systematic steps in the prevention and manage-
ent of tuberculosis. Evidence abound that most of the adverse
ffects due to the antituberculous and antiretroviral drugs are expe-
ienced during the ﬁrst months of therapy [17]. For instance, two
uthors at different times have reported nephritis associated with
ifampicin [18,19]. Still, there exist cross adverse event among
ifampicin, isoniazid, and pyrazinamide which is manifested as
iver injury [20–23] while ethambutol is widely known for its ocu-
ar toxicity [24]. Extensions of their adverse effects include skin
ashes, gastrointestinal intolerance, central nervous system symp-
oms, peripheral neuropathy, and blood dyscrasias. In respect to the
forementioned, the concern about adverse drug effects of anti-
uberculous agents has been advocated [25,26] because of their
egative impacts on the sustainability of public health system [6,7].
ince tuberculosis affects people in their productive and reproduc-
ive age, but available data on adverse drug reactions in patients
nd animals experiments particularly with respect to reproduction
re limited [27]. Although our previous studies showed synergy
f ﬁxed-dose combined antituberculous drugs in liver injury, its
eratogenic potential in a ﬁrst ﬁlial generation of animals model as
ell as the activity of antioxidants against the toxicity of rifampicin
nd the ﬁxed-dose combined antituberculous [25,28]. There is still a
aucity of data on the reproductive toxicity of ﬁxed-dose combined
ntituberculous drugs.
Therefore, in this present study, we assessed the reproductive
oxicity of combined ﬁxed-dose ﬁrst-line anti-tuberculosis (CFDAT)
rugs in rats.
. Materials and methods
.1. Drugs and chemicals
A Combined ﬁxed-dose antituberculous drugs consisting of
ifampicin (150 mg), isoniazid (75 mg), Pyrazinamide (400 mg)  and
thambutol (275 mg)  per tablet, was obtained from the DOTS
linic of Akerele Primary Healthcare Centre, Nigeria. Thiobarbi-
uric acid (TBA) was purchased from Sigma Chemical Company
USA). Metaphosphoric acid, Reduced glutathione (GSH), and
richloroacetic acid (TCA) were purchased from J.I. Baker (USA).
at Follicle Stimulating Hormone (FSH) (Cat. No.: Rshakrfs-010R)
nd Luteinizing Hormone (LH) ELISA (Rshakrlh-010SR) kits were
urchased from (Biovendor, Shibayagi Co., Ltd. (Japan). RAT
estosterone (RTC001R) and Prolactin ELISA were obtained from
iovendor, Laboratorni, medicina a.s Karasek (Czech Republic).
at oestrogen ELISA (CSB-E07279r) (Cusabio Biotech CO., LTD.)
nd Progesterone (RTC008R) kit was purchased from Biovendor,
aboratorni, medicina a.s Karasek (Czech Republic) and Sodium
ydroxide from MERCK (Germany). All other chemicals and
eagents used were of analytical grades. Atomic UV/Visible Spec-
rophotometer obtained from JENWAY, Bibby Scientiﬁc (Model
300 and 7305) (USA).
.2. Animals
Albino rats of the Wistar strain weighing between 120 and 250 g
ere purchased from inbreeding animal house of the Redeemers
niversity, Mowe, Ogun State, Nigeria. The rats were housed in the
xperimental animal handling facility of the University of Lagos,
ollege of Medicine, Idi-Araba Campus, Lagos State, Nigeria, at
emperature of the experimental animal rooms of 22 ± 3 ◦C, under
ontrolled conditions with a 12 h light/12 h dark schedule and
ed with commercially available rat pelleted diet (Ladoke Akin-
ola Growers Mash) and water ad libitum throughout the period
f the experiment. Animals were acclimatized for a period of twoeports 3 (2016) 620–627 621
weeks before the experiment. The experimental protocols were
approved by the Institutional Animal Care and Use Committee,
Department of Pharmacology, Therapeutic and Toxicology, College
of Medicine, University of Lagos, and all of the experimental proce-
dures conformed to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. The institution animal health
ofﬁcers certify the animals ﬁt for the experiment. The beddings
of the animals were changed on alternate days and the animals
were sacriﬁced in a humane manner at the end of the experiment
by cervical dislocation. The investigation conforms to the Guide
for the Care and Use of Laboratory Animals published by the U. S.
National Institutes of Health (NIH Publication No. 85-23, revised
1996)” for studies involving experimental animals and the proce-
dures as documented by Kilkenny et al. [29] for reporting animal
research.
2.3. Sub-chronic study
Thirty-two (32) (n: male or female = 8) Wistar rats weighing
168.1 ± 8.0 g were divided into 4 groups of 8 rats per group for each
sex and treatment group. The control groups were administered
1.6 ml  distilled water by oral administration daily. A combined
ﬁxed-dose anti-TB drugs (92.5 mg/m2  per body surface area, p.o)
[30] was administered to the test groups (male and female sepa-
rately). The rats were weighed weekly and treatments lasted for
Forty-ﬁve (45)-days.
2.4. Collection of blood samples and tissues
All treatments were terminated on day 45 and Twenty-four
(24) hours following the last administration, blood samples were
obtained via ocular puncture into lithium heparinized bottles and
animals were sacriﬁced via cervical dislocation. The blood samples
containing anticoagulant were centrifuged at 4200 rpm for 5 min  to
obtain the clear supernatant (i.e. serum) from which all biochemi-
cal analyses were carried out. In addition, the reproductive organs
(testis, epididymis and ovaries) were removed, weighed and stored
for histological examinations.
2.5. Sperm function analysis
The testes from each rat were carefully exposed and removed
along with its adjoining epididymis. The left testis was  sepa-
rated from the epididymis, and the caudal epididymal tissue was
removed and placed in a petri dish containing 1 ml normal saline
solution. An incision of about 1 mm was  made in the caudal
epididymis to liberate its spermatozoa into the saline solution. Pro-
gressive sperm motility, sperm count, and sperm viability were
then examined under the microscope attached to a Celestron® dig-
ital microscope imager (Torrance, CA 90503) and viewed under
X40 objective according to the method described by Raji et al. [31]
Epididymal sperm motility was  assessed by calculating motile sper-
matozoa per unit area and was expressed as percentage motility.
Epididymal sperm counts were made using the improved Neubauer
hemocytometer and were expressed as million/ml of suspension.
The sperm viability was also determined using Eosin/Nigrosin stain.
The motile (live) sperm cells were unstained while the non-motile
(dead) sperms absorbed the stain. The stained and unstained sperm
cells were counted and an average value for each was recorded from
which percentage viability was calculated. Sperm morphology was
evaluated by staining the sperm smears on microscope slides with
two drops of Walls and Ewa  stain after they were air-dried. The
slides were examined under the microscope under oil immersion
with X 100 objectives.
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Table  1
Effects of Antituberculous Drugs on Male Reproductive Hormones in Rats.
FSH (U/l) LH (U/l) Testosterone (U/l)
Control 0.18 ± 0.10 0.26 ± 0.10 1.57 ± 0.30
RIPE  0.06 ± 0.02*(66.7)[80] 0.14 ± 0.04*(46.2)[60] 0.90 ± 0.10*(42.8)[66.7]
NB: Result expressed as Mean ± SEM; n = 8; Control (DW, Distilled water, 1.6 ml); Values in parenthesis represent% change; (−) increase; (+) decrease. () % mean, when
compared with control distilled water; [] SEM when compared with control. *p < 0.05 chang
(92.5  mg/m2 body surface area, body weight 60 kg man; Body Surface Area (BSA): man  = 1
Stimulating Hormone; LH = Luteinizing Hormone.
Fig. 1. Effects of anti-tuberculous drugs on anti-oxidant activities in rats,
Results expressed as Mean ± SEM; n = 8. Control (DW: Distilled Water,); RIPE:
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol), GSH: Reduced glutathione,
GST: Glutathione-S-transferase GPX: Glutathione peroxidase.
Fig. 2. Effects of anti-tuberculous drugs on anti-oxidant activities in rats,
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of substrate solution was  added to each well and incubated for
30 min  in the dark. This reaction was  terminated by the additionesult expressed as Mean ± SEM; n = 8. Control (DW: Distilled Water); RIPE:
ifampicin + Isoniazid + Pyrazinamide + Ethambutol), MDA: Malondialdehyde.
.6. Reproductive hormone assessments
Serum concentrations of male reproductive hormones were
easured using micro plate enzyme-linked immunosorbent assay
ELISA) and expressed as Units/l. Studies protocols were discussed
elow. Direct immune-enzymatic determination of the Luteiniz-
ng (LH) and Follicle-Stimulating Hormones (FSH) in human serum
ere determined by the methods of Odell et al. [32] based on the
anufacturer’s manual. Testosterone activity was determined fol-owing the principle described by Joshi et al. [33]. The method of
eVilla et al. [34] was followed in estimating the levels of proges-
erone and oestrogen levels while prolactin levels were determinede relative to control group. RIPE: Rifampicin + Isoniazid + Pyrazinamide + Ethambutol
.6; BSA rat (0.16 kg) = 0.025; km = Weight/BSA; km rat: 6; Km man: 37). FSH = Follicle
according to the method of Shome and Parlow [35] based on the
manufacturer’s manual.
2.6.1. Rat FSH and LH ELISA
Brieﬂy, in Rat FSH or LH ELISA Kit, biotin-conjugated anti-
FSH/anti-LH and standard or sample were incubated in monoclonal
anti-FSH antibody-coated wells. After 15 h incubation and wash-
ing, HRP (horse radish peroxidase)-conjugated avidin was added,
and incubated for 30 min. After washing, HRP-complex remain-
ing in wells was  reacted with a chromogenic substrate (TMB) for
20 min, and reaction was stopped by addition of acidic solution, and
absorbance of yellow product was measured spectrophotometri-
cally at 450 nm.  The absorbance is nearly proportional to FSH or LH
concentration. FSH or LH concentrations in unknown samples were
then exptrapolated via given their respected standard curve [32].
2.6.2. Rat testosterone ELISA
A 10 l of each of sample with new disposable tips into appropri-
ate wells was dispensed in a 100 l of incubation Buffer into each
well. Added was  a 50 l enzyme Conjugate into each well which
was incubated for 60 min  at room temperature on a microplate
mixer. This was  discarded and the well rinsed 4 times with diluted
washing solution (300 l per well). Then 200 l was  added of sub-
strate solution to each well and incubated standing for 30 min  in
the dark. The reaction was  stopped by adding 50 l of stop solu-
tion to each well and the absorbance determined for each well at
450 nm [33].
2.6.3. Rat estrogen ELISA
The blank well and or 50 l of standard in triplicate or sample
per well were prepared. Then added was a 50 l of HRP-conjugate
to each well except for the blank. Then 50 l antibody was added
to each well. The solution was  thorough mixed, and then incubated
for 3 h at 37 ◦C. Each well was washed with buffer (350 l), wait
10 s and spin. Following the last wash, remaining wash buffer was
aspirated. Plate was inverted and blotted against clean paper tow-
els. A 50 l of substrate A was  added and substrate B to each well,
and mixed. Solution was incubated for 15 min  at 37 ◦C. In a dark
environment, a 50 l of stop solution was added to each well. The
color change appeared uniform. Determination of the optical den-
sity was carried out within 10 min, using a microplate reader set to
450 nm [34].
2.6.4. Rat progesterone ELISA
A dispensed 25 l of each sample with new disposable tips into
appropriate wells and added 50 l of incubation Buffer into each
well. Added was  a 100 l enzyme conjugate into each well and
incubated for 1 h at 22 ± 2 ◦C on a microplate mixer. Following a
thorough rinsing up to 4 times with diluted wash solution, a 200 lof a 50 l of stop solution to each well. The progesterone level was
measured at 450 nm within 15 min  [34].
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Fig. 3. Effects of anti-tuberculous drugs on anti-oxidant activities in rats,
Result expressed as Mean ± SEM; n = 8. Control (DW: Distilled Water); RIPE:
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol), SOD: Superoxide dismutase,
CAT: Catalase, TP: Total Protein.O. Awodele et al. / Toxico
.6.5. Rat prolactin ELISA
A pipetted 25 l of each sample into the wells was prepared
nd added 50 l of rat prolactin sample buffer to every well. Shake
or 2 h at room temperature (22 ± 1 ◦C), rinsed 4 times with 300 l
uffered wash solution. A 200 l was added of enzyme-labeled
nti-rat prolactin antibody to all wells and shaken for 1 h, rinsed
gain for 4 times with 300 l buffered wash solution. A 200 l
f liquid TMB/substrate solution was added to all wells. This was
hen incubated standing for 30 min  in the dark. Then 50 l of stop
olution was added to each well, mixed carefully and measured at
50 nm [35].
.7. Antioxidants and oxidative stress
The method of Beutler et al. [36] was followed in estimating
he levels of glutathione (GSH). Glutathione-S-transferase (GST)
ctivity was determined according to Habig et al. [37]. The level
f superoxide dismutase (SOD) activity was determined by the
ethod of Misra and Fridovich [38]. Catalase (CAT) activity was
etermined according to the method of Sinha [39]. Glutathione Per-
xidase (GPx) activity was determined according to the method of
llerby and Bredesen [40]. Lipid peroxidation was  determined by
easuring the formation of thiobarbituric acid reactive substances
TBARS) according to the method of Varshney and Kale [41].
.8. Histological assessment
The tissue samples from the liver, kidney and heart for
istological examination were passed through the process of ﬁxa-
ion, dehydration, clearing, inﬁltration, embedding, sectioning and
taining. To ensure good ﬁxation, the tissues were trimmed to about
 mm thickness, so as to obtain good ﬁxation. The tissues were then
xed in 10% formol saline and were then transferred to 50% alcohol
70%, 80%, 85%, 95 and 100%), for two hours. Alcohol was  removed
rom the treated tissues by titrating them through ﬁrst an equal
ixture 100% (absolute) alcohol and xylene for one hour each in
hat order. Inﬁltration was carried out twice by passing each tissue
hrough molten parafﬁn wax in an oven at a temperature of 30 ◦C
or one and a half hours each. The tissues so embedded in molten
arafﬁn wax were later placed on a wooden block and trimmed
o size. Serial sections 10 ms  thick were made using a rotatory
icrotome. The cut sections were then ﬂoated in a warm water
ath at a temperature of 30–40 ◦C and were placed slides. Eight
ections were obtained from each treated organ from each animal.
our samples were placed on each slides. Microscopic examination
as done by using varying magniﬁcations of 10, 40, 100 and 400 to
etermine if the samples were properly ﬁxed on the slide. Follow-
ng staining, mounting of sections was carried out using dimethyl
arafﬁnate xylene (DPX) as a mounting agent, after which micro-
copic examination was done.
. Statistical analysis of data
All data were expressed as mean ± standard error of mean
SEM). Signiﬁcant differences among the group were determined
y one-way analysis of variance (ANOVA) and student T-test using
he statistical analysis programme for social sciences (SPSS). Post
oc testing was performed for inter-group comparisons using the
east signiﬁcant difference (LSD) [42]. Graphical presentations were
chieved using GraphPad Prism 6. Results were considered to be
igniﬁcant at p ≤ 0.05..1. Male reproductive hormones
Table 1 shows the effects of RIPE in normal and treated rats.
IPE produces a signiﬁcantly (p < 0.05) reduced serum luteinizing,Fig. 4. Effects of anti-tuberculous drugs on anti-oxidant activities in male rats,
Result expressed as Mean ± SEM; n = 8. Control (DW: Distilled Water); RIPE:
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol).
follicle stimulating hormone and testosterone by 46.2%, 66.7% and
42.7% respectively when compared with control.
3.2. Assessment of female reproductive hormones in rats
The results of the female reproductive hormones in rats are
presented in Table 2. From the result obtained serum oestro-
gen, prolactin and progesterone levels were increased in animals
administered with RIPE by 191.7% (p < 0.05), 33.3% (p > 0.05) and
350% (p < 0.05) respectively when compared with control distilled
water group.
3.3. Antioxidants activities
Figs. 1 and 2: show that superoxide dismutase, glutathione-S-
transferase, glutathione peroxidase, reduced glutathione, as well as
lipid peroxidation were not signiﬁcantly (p > 0.05) altered in RIPE-
treated rats this study experiment.3.4. Total protein and catalase
Fig. 3: shows the results of the effect of RIPE on total protein
and catalase levels in male and female rats. There were decreased
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Table  2
Effects of Antituberculous Drugs on Female Reproductive Hormones in Rats.
Oestroge (U/l) Prolactin (U/l) Progesterone (U/l)
Control 0.36 ± 0.12 0.06 ± 0.03 0.12 ± 0.05
RIPE  1.05 ± 0.21*(−191.7) [−75] 0.08 ± 0.03 (−33.3) [0] 0.54 ± 0.25*(−350.0)[−400]
NB: Result expressed as Mean ± SEM; n = 8; Control (DW: Distilled Water, 1.6 ml); Values 
pared  with control distilled water; [] SEM when compared with control. *p < 0.05 change r
(92.5  mg/m2 body surface area, body weight 60 kg man; Body Surface Area (BSA): man  = 1
Fig. 5. Effects of anti-tuberculous drugs on anti-oxidant activities in rats,
Result expressed as Mean ± SEM; n = 8; Control (DW: Distilled Water); RIPE:
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sperm counts while asking the question to whether such wouldifampicin + Isoniazid + Pyrazinamide + Ethambutol).
p < 0.05) in total protein by 24% (male) while catalase increases by
3% in RIPE treated male but not female rats.
.5. Sperm characteristics
Fig. 4: shows the result of RIPE on sperm characteristics and
orphology in normal and treated male rats. Sperm counts and
he percentage of spermatozoa moving actively (motility) forward
ecreased by 27.3% and 16.1% respectively when compared with
ontrol distilled water group.
.6. Organ system weights in rats
Fig. 5: shows ovary, testis, and epididymis weights expressed
er body weight. Treatments with RIPE caused an increased ovary
eight by 13.8% signiﬁcantly (p > 0.05). Testis weight was  also
ecreased, although, insigniﬁcantly by 33.6% (p < 0.05). However,
he epididymis was unaltered in all animals.
Fig. 6 shows the photomicrograph showing testes of the control
at. (1.6 ml  distilled water) (left) and treated rat (RIPE; 92.5 mg/m2
er body surface area) (right). The treated rat shows congested
essels below the tunica as indicated by their dilation and their
ngorgement, as shown by the arrows.
Fig. 7 shows the epididymis showing sperm cells, sterocilia,
asal cells, expanded stroma with proliferated blood vessels (thin
rrows) control rat (1.6 ml  distilled water) (left) and increased
troma and intra-epithelial lymphocytes (large arrows, more pro-
ounced) in the treated rat (RIPE; 92.5 mg/m2 per body surface
rea) (right).
Fig. 8 shows normal ovaries (thin arrows) and normal fallopian
ubes (double headed arrows) of the control rat (1.6 ml  distilled
ater) (left) and treated rat.in parenthesis represent% change; (−) increase; (+) decrease. () % mean, when com-
elative to control group. RIPE: (Rifampicin + Isoniazid + Pyrazinamide + Ethambutol,
.6; BSA rat (0.16 kg) = 0.025; km = Weight/BSA; km rat: 6; Km man: 37).
4. Discussion
The combination therapy used in TB management has in no
doubt signiﬁcantly improved the outcome of the management [43],
although, individual agent retain its known functional activities.
Nevertheless, there are major challenges in the treatment options
which have been reviewed by WHO  [7]. Several of such setbacks
also have contributed in recent years to a resurgence of interest
in developing improved therapies to treat TB. Thus, in a pragmatic
matter, comparative studies have pondered on the issue of toxic-
ity in order to add to database information [6] related to survival,
disability and capacity for functioning in daily life [7]. However,
when information indicates that a particular species is more rel-
evant for assessing human risk, the human equivalent dose for
that species is suggested to be used in subsequent calculations,
regardless of whether this species is the most sensitive [44]. This
aforementioned has translated into an advocacy that the body sur-
face area correlates well across several mammalian species with
several parameters of biology, including oxygen utilization, caloric
expenditure, basal metabolism, blood volume, circulating plasma
proteins, and renal function [44]. Thus, if serious toxicities are
observed in an animal species considered less relevant, those toxi-
cities might be taken into consideration in determining the species
to be used to calculate an human equivalent dose [44,45].
Previous reports of some notable adverse drug reactions include
weight increase and hepatotoxicity [29,45], reproductive toxicity
[29], exanthema, hematological [46] among others when RIPE is
used either as the sole agent or together. In fact, antituberculo-
sis drug-induced hepatotoxicity has been reviewed [47]. According
to WHO  report on the Global project on antituberculous drug
Resistance Surveillance, adverse effects of RIPE have chopped up
into diminishing treatment effectiveness because they signiﬁcantly
contribute to treatment failure while relapse or the emergence
of drug-resistance are now routinely encountered [48]. Further-
more, weight increase or reduction can be clinically relevant in
the prediction of TB treatment outcome because changes in weight
have been observed from the ﬁrst month of therapy [49–51]. Thus,
weight gain is often used to predict the TB treatment outcomes. In
respect, we  also observed weight changes with respect to the com-
bined ﬁxed-dose ﬁrst-line antituberculosis (CFDAT). There were
reduced testicular and epididymis weights in RIPE treated animals,
(Fig. 5), whereas, contrastingly, the ovaries increased. Although,
our study did not assess the mechanism involved in weight alter-
ations, however, it is hoped that such alteration in weights during
treatment might have been due, in part, to responses triggered by
anti-TB drugs (4). Also, we obtained decreased in sperm counts
and motility (Fig. 4), although, insigniﬁcant statistically, with no
alteration in sperm morphological abnormality in RIPE treated rats.
This decreased in sperm quality was conﬁrmed by the histologi-
cal changes due to congested vessels in peritesticular and Leydig
cells of the stroma in the testes of the experimental rats treated
with RIPE (Fig. 7). It agrees also with our previous report on RIPE
[25]. A study by Joffe [52] has however linked male fertility withreﬂect a general reduction in male fertility, especially among the
TB patients. In animals receiving RIPE, several intraepithelial lym-
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Fig. 6. Photomicrograph showing testes of the control rat (1.6 ml distilled water) (left) and treated rat (RIPE; 92.5 mg/m2 per body surface area) (right). The treated rat shows
congested vessels below the tunica, as shown by the arrows. [H&E, x400]. RIPE: Combined ﬁxed-dose Rifampicin, Isoniazid, Pyrazinamide, Ethambutol.
Fig. 7. The epididymis showing sperm cells, sterocilia, basal cells, expanded stroma with proliferated blood vessels (thin arrows) Control (1.6 ml  distilled water) (left) and
increased stroma and intra-epithelial lymphocytes (large arrows, more pronounced) in the treated rat (RIPE; 92.5 mg/m2 per body surface area) (right). [H&E, x400]. RIPE:
Combined ﬁxed-dose Rifampicin, Isoniazid, Pyrazinamide, Ethambutol.
F  arrow
9  Rifam
p
a
a
o
t
p
c
Hig. 8. Normal ovaries (thin arrows) and normal fallopian tubes (double headed
2.5  mg/m2 per body surface area) (right). [H&E, x400]. RIPE: Combined ﬁxed-dose
hocytes and macrophages were scattered throughout the tissue
nd the stroma became expanded with proliferated small vessels
s opposed to few present in normal rats. Also, in Fig. 6, the testes
f the treated rat show congested vessels below the tunica while
he epididymis shows increased stroma and intra-epithelial lym-
hocytes in the treated male rat (Fig. 7). The mild inﬂammation
an predispose to a mother disease when cause is not maximized.
owever, both the ovaries and fallopian tubes of the treated rats) of the control rat Control (1.6 ml distilled water) (left) and treated rat (RIPE;
picin, Isoniazid, Pyrazinamide, Ethambutol.
were unaltered throughout the experiment (Fig. 8 shows). Thus,
indicates further that caution must be exercise due to the tendency
to obtain toxicity during a prolong use. More so, Serum LH and FSH
and testosterone levels were reduced in treated male rats (Table 1).
Thus, indicating the potential role of RIPE in the general reduction
of male fertility, although, our study is limited in that it falls below
such a duration that would adjudge RIPE anti-gonadal properties
and did not evaluate reproductive behavior.
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Conversely, serum oestrogen, prolactin, and progesterone levels
ere elevated in treated female rats (Table 2). This brings an insight
o further ponder on Peloquin [53] suggestion on the essentiality of
herapeutic drug monitoring in the treatment of tuberculosis which
ay  help identify peak levels of biological enzymes due to the use
f CFDAT drugs while providing some solutions and thereby resolve
ssues of drug interactions prior to treatment failure relapse or tox-
city. Reports of different authors from different parts of the world
ave at different times reported Isoniazid-induced gynaecomastia
54–57]. Similarly, such cross activity has been found associated
ith thioacetazone and ethionamide [58–60]. Isoniazid-induced
ynaecomastia has been linked in part to modulation of weight,
onadotrophin secretion, and gonadal functions [56]. Presently,
ntituberculous chemotherapy is rarely known to cause gynaeco-
astia unlike the sex hormones, antiandrogens, spironolactone,
imetidine, verapamil and alkylating agents. In addition, studies
ndicating this abnormality are few and scanty.
Further, oxidative stress results from an imbalance between
xidants and antioxidants in favor of the oxidants, but, whether
his is involved in antituberculous drug-induced toxicity has been
ebated. Some studies from basic to clinical applications have
oncluded that both non-enzymatic and enzymatic antioxidant
ystems play major roles in the detoxiﬁcation of reactive oxygen
pecies [61]. In addition, reports that diminishing levels of activity
f any of these enzymes such as glutathione-S-transferase, cata-
ase, and superoxide dismutase activities and glutathione levels
ollowing antituberculous agents administration in rats may  indi-
ate oxidative stress and may  confer thereafter, in part, some levels
f toxicity [62–64]. From the result obtained given RIPE, cata-
ase levels and total protein levels in male but not female rats
ecreased signiﬁcantly (Fig. 3). We  have previously reported a
ondition of diminished catalase and other oxidative parameters
uring hepatotoxicity achieved through a combination of zidovu-
ine and combined antituberculous agents in rats [28]. A study
y Chowdhury et al. [64] has reported that TB patients on receiv-
ng antituberculous therapy have been shown to have reduced
lasma levels of glutathione and higher malondialdehyde due to
xidative stress from the antituberculous therapy, although, the
echanism for the later was not apparent. In this study, reduced
lutathione, superoxide dismutase, lipid peroxidation, glutathione-
-transferase, glutathione peroxidase were altered in the treated
ats. RIPE modulation of antioxidant status in vivo in this study
s typical as most antituberculous agents have been reported to
nterfere with liver biotransformation (28,62,63,64)
. Conclusion
The present study demonstrates the tendency of RIPE to cause
eproductive toxicity in the rat. Thus, this may  suggest that param-
ters associated with reproductive activity be monitored during
ntituberculous chemotherapy.
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